Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2172-2181

  Wilson, Lauren E ^a   Pawlita, Michael ^b   Castle, Phillip E ^c   Waterboer, Tim ^b   Sahasrabuddhe, Vikrant ^a   Gravitt, Patti E ^d   Schiffman, Mark ^a   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Global Cancer Initiative   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

antibodies; human papillomavirus; seroepidemiology

Indexed keywords

GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE L1; HYBRID PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CORRELATION ANALYSIS; CYTOLOGY; DNA DETERMINATION; DNA TUMOR VIRUS; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE; SEXUAL BEHAVIOR; SMOKING; UTERINE CERVIX CANCER;

ANTIBODIES; HUMAN PAPILLOMAVIRUS; SEROEPIDEMIOLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84882576738     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28215     Document Type: Article

References (43)

1. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204.
2. Parkin DM, Bray F,. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24: S11-S25.
3. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
4. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123-37.
5. Koshiol JE, Schroeder JC, Jamieson DJ, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006; 119: 1623-9.
6. Xi LF, Carter JJ, Galloway DA, et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 2002; 11: 343-51.
7. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-9.
8. Stanley M,. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109: S15-S21.
9. Hebner CM, Wilson R, Rader J, et al. Human papillomaviruses target the double-stranded RNA protein kinase pathway. J Gen Virol 2006; 87: 3183-93.
10. Mota F, Rayment N, Chong S, et al. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol 1999; 116: 33-40.
11. Wang SS, Schiffman M, Shields TS, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10,000 women in Costa Rica. Br J Cancer 2003; 89: 1248-54.
12. Heiligenberg M, Michael K, Kramer M, et al. Seroprevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population based study in Amsterdam. Sex Transm Dis 2010; 37: 672-80.
13. Porras C, Bennett C, Safaeian M, et al. Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis 2010; 10: 238.
14. Wideroff L, Schiffman M, Hoover R, et al. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. J Infect Dis 1996; 174: 937-43.
15. Coseo S, Porras C, Hildesheim A, et al. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Sex Transm Dis 2010; 37: 706-14.
16. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173: 1394-8.
17. Wentzensen N, Wilson LE, Wheeler CM, et al. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. Cancer Res 2010; 70: 8578-86.
18. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102: 1653-62.
19. Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study. J Infect Dis 2011; 204: 94-102.
20. Schiffman M, Safaeian M, Wentzensen N,. The use of human papillomavirus seroepidemiology to inform vaccine policy. Sex Transm Dis 2009; 36: 675-9.
21. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005; 51: 1845-53.
22. Faust H, Knekt P, Forslund O, et al. Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. J Gen Virol 2010; 91: 1840-8.
23. Guido R, Schiffman M, Solomon D, et al. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003; 188: 1401-5.
24. Sehr P, Müller M, Höpfl R, et al. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002; 106: 61-70.
25. Clifford G, Shin H, Oh J, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007; 16: 1874-9.
26. Wang SS, Schiffman M, Herrero R, et al. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10,000 women in Costa Rica. Br J Cancer 2004; 91: 1269-74.
27. Markt SC, Rodriguez AC, Burk RD, et al. Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting. J Infect Dis 2012; 205: 498-505.
28. Paaso AE, Louvanto K, Syrjänen KJ, et al. Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. J Gen Virol 2011; 92: 2034-46.
29. Touze A, de Sanjose S, Coursaget P, et al. Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 2001; 39: 4344-8.
30. Skjeldestad FE, Mehta V, Sings HL, et al. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008; 87: 81-8.
31. Rizk RZ, Christensen ND, Michael KM, et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 2008; 89: 117-29.
32. Bedoya AM, Gaviria AM, Baena A, et al. Age-specific seroprevalence of human papillomavirus 16, 18, 31, and 58 in women of a rural town of Colombia. Int J Gynecol Cancer 2012; 22: 303-10.
33. Simen-Kapeu A, Kataja V, Yliskoski M, et al. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand J Infect Dis 2008; 40: 745-51.
34. Ferson M, Edwards A, Lind A, et al. Low natural-killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer 1979; 23: 603-9.
35. Gunsolley JC, Pandey JP, Quinn SM, et al. The effect of race, smoking and immunoglobulin allotypes on IgG subclass concentrations. J Periodontal Res 1997; 32: 381-7.
36. Tollerud DJ, Brown LM, Blattner WA, et al. Racial differences in serum immunoglobulin levels: relationship to cigarette smoking, T-cell subsets, and soluble interleukin-2 receptors. J Clin Lab Anal 1995; 9: 37-41.
37. Obeid P, Bercy P,. Effects of cigarette smoking on periodontal health: a review. Adv Ther 2000; 17: 230-7.
38. Fischbacher CM, Bhopal R, Blackwell CC, et al. IgG is higher in South Asians than Europeans: does infection contribute to ethnic variation in cardiovascular disease? Arterioscler Thromb Vasc Biol 2003; 23: 703-4.
39. Geng Y, Savage SM, Razani-Boroujerdi S, et al. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T-cell anergy. J Immunol 1996; 156: 2384-90.
40. Singh SP,. Acute and chronic nicotine exposures modulate the immune system through different pathways. Toxicol Appl Pharmacol 2000; 164: 65-72.
41. Sopori ML, Kozak W, Savage SM, et al. Nicotine-induced modulation of T-cell function: implications for inflammation and infection. Adv Exp Med Biol 1998; 437: 279-89.
42. Koshiol J, Schroeder J, Jamieson DJ, et al. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol 2006; 164: 176-83.
43. Sarian LO, Hammes LS, Longatto-Filho A, et al. Increased risk of oncogenic human papillomavirus infections and incident high-grade cervical intraepithelial neoplasia among smokers: experience from the Latin American screening study. Sex Transm Dis 2009; 36: 241-8.